According to a study published today in the Journal of the National Cancer Institute, there are inherent limitations in the current pathology methodology used in protein biomarker studies. Use of Automated Quantitative Analysis (AQUA(TM)) technology from HistoRx, Inc. elucidated that the concentration of antibodies used as tags to identify biomarkers of interest in patient tissue dramatically affects the apparent relationship between the biomarker’s expression and clinical outcome. These findings are particularly relevant to translational medicine, as the relationship between protein expression and disease gains an increasing role in the way physicians treat patients and individualize therapeutic regimes.
